Revenue climbed 11% to $1.72 billion during the period, comfortably exceeding analyst projections of $1.68 billion. Adjusted earnings reached 80 cents a share, outperforming the consensus estimate of 74 cents.

Following these results, the company tightened its full-year adjusted earnings guidance to a range of $2.97 to $3.05 per share. The upward revision reflects sustained momentum in core business areas, as healthcare providers continue to see higher demand for the company’s specialized cardiovascular devices.